Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pharmaceutical Industry News Roundup: Pipeline Changes, Clinical Trials, and Acquisitions

Pharmaceutical Industry News Roundup: Pipeline Changes, Clinical Trials, and Acquisitions

Incyte Corporation has announced a significant restructuring of its research and development pipeline, discontinuing three drug prospects to focus on what CEO Bill Meury calls "high-value programs." The company has halted development of povorcitinib for chronic urticarias, as well as two other compounds, INCA034460 for vitiligo and INCB57643 for myelofibrosis. This strategic shift comes as Incyte prepares for the expiration of the main patent protecting its top-selling drug, Jakafi, later this decade.

NoahAI News10/28/2025
Edesa Biotech Reports Promising Results in Phase 3 Respiratory Failure Trial

Edesa Biotech Reports Promising Results in Phase 3 Respiratory Failure Trial

Edesa Biotech has unveiled encouraging data from its truncated phase 3 trial investigating the efficacy of paridiprubart (EB05) in treating acute respiratory distress syndrome (ARDS) caused by COVID-19. The anti-TLR4 antibody demonstrated improvements in both survival rates and recovery outcomes among critically ill patients.

NoahAI News10/28/2025
Jupiter Endovascular's Vertex TFX Catheter Platform Shows Promise in First-in-Human Trial

Jupiter Endovascular's Vertex TFX Catheter Platform Shows Promise in First-in-Human Trial

Jupiter Endovascular, a company formed by Neptune Medical just over a year ago, has announced positive results from the first-in-human trial of its innovative Vertex TFX catheter platform. The study, known as SPIRARE I, focused on treating patients with acute, intermediate-risk pulmonary embolism and demonstrated encouraging outcomes in both safety and efficacy.

NoahAI News10/28/2025
Roche's Gazyva Expands into Lupus Nephritis, Shows Promise in Idiopathic Nephrotic Syndrome

Roche's Gazyva Expands into Lupus Nephritis, Shows Promise in Idiopathic Nephrotic Syndrome

Roche's CD20-targeting antibody Gazyva (obinutuzumab) has secured a significant expansion beyond its original oncology indications, marking a new chapter in the treatment of immune-mediated kidney conditions. The drug, initially approved in 2013 for chronic lymphocytic leukemia, has now received FDA clearance for lupus nephritis and demonstrated positive results in a phase 3 trial for idiopathic nephrotic syndrome.

NoahAI News10/28/2025
CSL Delays Vaccine Unit Spinoff as US Flu Immunization Rates Plummet

CSL Delays Vaccine Unit Spinoff as US Flu Immunization Rates Plummet

CSL, a major player in the pharmaceutical industry, has announced a delay in its plans to spin off its vaccine division, CSL Seqirus, citing unexpected volatility in the US influenza vaccine market. The decision comes as flu vaccination rates in the United States have fallen dramatically, prompting concerns about public health and the financial outlook for vaccine manufacturers.

NoahAI News10/28/2025
Labcorp Reports Strong Q3 Growth, Adjusts Full-Year Outlook

Labcorp Reports Strong Q3 Growth, Adjusts Full-Year Outlook

Labcorp, a leading global life sciences company, has announced its third-quarter results for 2025, showcasing robust growth across its primary business segments while adjusting its full-year revenue forecast. The company's performance reflects the ongoing dynamics in the diagnostics and pharmaceutical services sectors.

NoahAI News10/28/2025
Incyte Discontinues BET Inhibitor Program Amid Industry-Wide Safety Concerns

Incyte Discontinues BET Inhibitor Program Amid Industry-Wide Safety Concerns

Incyte Corporation has announced the discontinuation of its BET inhibitor program, marking a significant shift in the company's research and development priorities. This decision comes against a backdrop of growing safety concerns surrounding the BET inhibitor drug class across the pharmaceutical industry.

NoahAI News10/28/2025
Aldeyra Therapeutics Reshuffles Pipeline, Discontinues ADX-629 Development

Aldeyra Therapeutics Reshuffles Pipeline, Discontinues ADX-629 Development

Aldeyra Therapeutics, a biopharmaceutical company focusing on novel therapies for immune-mediated diseases, has announced significant changes to its drug development pipeline. The company's decision to halt clinical development of one asset and reprioritize others comes in response to recent clinical data and strategic assessments.

NoahAI News10/28/2025
Zag Bio Emerges with $80 Million to Target Thymus for Autoimmune Disease Treatment

Zag Bio Emerges with $80 Million to Target Thymus for Autoimmune Disease Treatment

Zag Bio, a new player in the pharmaceutical industry, has announced its emergence from stealth mode with $80 million in funding and ambitious plans to revolutionize the treatment of autoimmune diseases. The company's innovative approach focuses on targeting the thymus gland to induce immune tolerance, potentially offering new hope for patients with conditions such as Type 1 diabetes.

NoahAI News10/28/2025
GSK Expands COPD Pipeline with $745M Deal for Empirico's Oligonucleotide Therapy

GSK Expands COPD Pipeline with $745M Deal for Empirico's Oligonucleotide Therapy

GlaxoSmithKline (GSK) has inked a substantial deal with Empirico, signaling a renewed focus on oligonucleotide therapies and bolstering its chronic obstructive pulmonary disease (COPD) portfolio. The agreement, which could reach $745 million, centers on EMP-012, a siRNA oligonucleotide already in phase 1 clinical trials for COPD.

NoahAI News10/28/2025
Lonza Acquires Rapid Microbial Testing Firm Redberry SAS to Accelerate Quality Control in Pharma Industry

Lonza Acquires Rapid Microbial Testing Firm Redberry SAS to Accelerate Quality Control in Pharma Industry

Swiss contract development and manufacturing organization (CDMO) Lonza has announced its acquisition of French rapid microbiology testing firm Redberry SAS, in a strategic move to enhance and expedite quality control testing for the pharmaceutical industry. The deal, revealed on October 27, 2025, aims to address the growing demand for faster product releases without compromising safety or regulatory compliance.

NoahAI News10/28/2025
BioMarin to Divest Hemophilia Gene Therapy Roctavian Amid Slow Sales

BioMarin to Divest Hemophilia Gene Therapy Roctavian Amid Slow Sales

BioMarin Pharmaceutical has announced plans to divest Roctavian, its gene therapy for hemophilia A, following disappointing sales and uptake since its launch three years ago. The decision marks a significant shift for a product once hailed as a potential blockbuster and highlights the ongoing challenges in commercializing gene therapies.

NoahAI News10/28/2025
«1...171819...67»